Arcellx, Inc. (ACLX)
Apr 28, 2026 - ACLX was delisted (reason: acquired by GILD)
115.07
0.00 (0.00%)
Inactive · Last trade price on Apr 27, 2026
Arcellx Revenue
In the year 2025, Arcellx had annual revenue of $22.29M, down -79.35%. Arcellx had revenue of $1.65M in the quarter ending December 31, 2025, a decrease of -89.17%.
Revenue (ttm)
$22.29M
Revenue Growth
-79.35%
P/S Ratio
302.95
Revenue / Employee
$106,632
Employees
209
Market Cap
6.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.29M | -85.65M | -79.35% |
| Dec 31, 2024 | 107.94M | -2.38M | -2.16% |
| Dec 31, 2023 | 110.32M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionACLX News
- 3 days ago - Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
- 6 weeks ago - Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders - GlobeNewsWire
- 6 weeks ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
- 2 months ago - Top 2 Health Care Stocks That May Crash This Quarter - Benzinga
- 2 months ago - Here's Why Shares of Arcellx Are Up Almost 80% Today - Investopedia
- 2 months ago - Why is Arcellx stock up 80% today? Gilead's $7.8B answer - Invezz
- 2 months ago - Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - Reuters
- 2 months ago - Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion - WSJ